CD274 and gastroesophageal junction adenocarcinoma: ICIs targeting the PD-1/PD-L1 pathway, such as nivolumab and sintilimab, have been proved to show good antitumor activity and safety in advanced G/GEJ adenocarcinoma [16, 17].